Details

Autor(en) / Beteiligte

• Le Rouzic, Adrien
• Fix, Jenna
• Vinck, Robin
• Kappler-Gratias, Sandrine
• Volmer, Romain
• Gallardo, Franck
• Eléouët, Jean-François
• Keck, Mathilde
• Cintrat, Jean-Christophe
• Barbier, Julien
• Gillet, Daniel
• Galloux, Marie

Titel

A New Derivative of Retro-2 Displays Antiviral Activity against Respiratory Syncytial Virus

Ist Teil von

• International journal of molecular sciences, 2024-01, Vol.25 (1), p.415

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2024

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• Human respiratory syncytial virus (hRSV) is the most common cause of bronchiolitis and pneumonia in newborns, with all children being infected before the age of two. Reinfections are very common throughout life and can cause severe respiratory infections in the elderly and immunocompromised adults. Although vaccines and preventive antibodies have recently been licensed for use in specific subpopulations of patients, there is still no therapeutic treatment commonly available for these infections. Here, we investigated the potential antiviral activity of Retro-2.2, a derivative of the cellular retrograde transport inhibitor Retro-2, against hRSV. We show that Retro-2.2 inhibits hRSV replication in cell culture and impairs the ability of hRSV to form syncytia. Our results suggest that Retro-2.2 treatment affects virus spread by disrupting the trafficking of the viral de novo synthetized F and G glycoproteins to the plasma membrane, leading to a defect in virion morphogenesis. Taken together, our data show that targeting intracellular transport may be an effective strategy against hRSV infection.